Cited 56 times in
A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민유홍 | - |
dc.date.accessioned | 2014-12-20T17:18:35Z | - |
dc.date.available | 2014-12-20T17:18:35Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0390-6078 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94356 | - |
dc.description.abstract | BACKGROUND: Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. DESIGN AND METHODS: Decitabine 20 mg/m(2)/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate. RESULTS: A total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69-595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progression-free survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials. CONCLUSIONS: Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1441~1447 | - |
dc.relation.isPartOf | HAEMATOLOGICA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/adverse effects | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/therapeutic use* | - |
dc.subject.MESH | Azacitidine/adverse effects | - |
dc.subject.MESH | Azacitidine/analogs & derivatives* | - |
dc.subject.MESH | Azacitidine/therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | MyelodysplasticSyndromes/diagnosis | - |
dc.subject.MESH | MyelodysplasticSyndromes/drug therapy* | - |
dc.subject.MESH | MyelodysplasticSyndromes/mortality | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | ProspectiveStudies | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Transplantation, Homologous | - |
dc.subject.MESH | TreatmentOutcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Je-Hwan Lee | - |
dc.contributor.googleauthor | Jun Ho Jang | - |
dc.contributor.googleauthor | Jinny Park | - |
dc.contributor.googleauthor | Seonyang Park | - |
dc.contributor.googleauthor | Young-Don Joo | - |
dc.contributor.googleauthor | Yeo-Kyeoung Kim | - |
dc.contributor.googleauthor | Hoon-Gu Kim | - |
dc.contributor.googleauthor | Chul Won Choi | - |
dc.contributor.googleauthor | Sung-Hyun Kim | - |
dc.contributor.googleauthor | Seong Kyu Park | - |
dc.contributor.googleauthor | Eunkyung Park | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.identifier.doi | 10.3324/haematol.2011.046078 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01407 | - |
dc.relation.journalcode | J00959 | - |
dc.identifier.eissn | 1592-8721 | - |
dc.identifier.pmid | 21659363 | - |
dc.subject.keyword | MDS, decitabine | - |
dc.subject.keyword | observational study | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 96 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1441 | - |
dc.citation.endPage | 1447 | - |
dc.identifier.bibliographicCitation | HAEMATOLOGICA, Vol.96(10) : 1441-1447, 2011 | - |
dc.identifier.rimsid | 27568 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.